Nonlinear Relationship of Retinal Thickness and Visual Acuity in Central Retinal and Hemiretinal Vein Occlusion

被引:5
|
作者
Scott, Ingrid U. [1 ]
Oden, Neal L. [2 ]
Vanveldhuisen, Paul C. [2 ]
Michael, S. [3 ]
Blodi, B. A. [4 ]
机构
[1] Penn State Coll Med, Dept Ophthalmol & Publ Hlth Sci, Hershey, PA USA
[2] Emmes, Rockville, MD USA
[3] Univ Calif Los Angeles, Doheny Eye Inst, Los Angeles, CA USA
[4] Univ Wisconsin, Fundus Photograph Reading Ctr, Madison, WI USA
基金
美国国家卫生研究院;
关键词
Anti-VEGF treatment; Central retinal vein occlusion; Central subfield thickness visual acuity; Hemiretinal vein occlusion; MACULAR EDEMA SECONDARY; OPTICAL COHERENCE TOMOGRAPHY; INTRAVITREAL TRIAMCINOLONE; LASER TREATMENT; STANDARD-CARE; TRAP-EYE; SHEATHOTOMY; VITRECTOMY; EFFICACY; SAFETY;
D O I
10.1016/j.ophtha.2023.05.023
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To investigate whether a nonlinear association between central subfield thickness (CST) on spectral-domain OCT and concurrent visual acuity letter score (VALS) exists in eyes treated initially with afli-bercept or bevacizumab for macular edema associated with central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO) in the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2). Design: Long-term follow-up after a randomized clinical trial from 64 centers in the United States.Participants: Participants were followed up to 60 months and treated at investigator discretion after completing the 12-month treatment protocol.Methods: Two-segment linear regression models were compared with simple linear regression models of VALS on CST. Pearson correlation coefficients were calculated to assess strength of CST and VALS associations.Main Outcome Measures: Central subfield thickness was measured by OCT and VALS by the electronic Early Treatment Diabetic Retinopathy Study methodology. Results: Estimated inflection points, reflecting turning points at which the CST and VALS association changes from positive to negative, calculated at 7 postbaseline visits, range from 217 to 256 mm. A strongly positive cor-relation exists to the left of each estimated inflection point, ranging from 0.29 (P < 0.01 at month 60) to 0.50 (P < 0.01 at month 12), and a strongly negative correlation exists to the right of each estimated inflection point, ranging from-0.43 (P < 0.01 at month 1) to-0.74 (P < 0.01 at month 24). Randomization statistical tests showed that 2-segment models are favored over 1-segment models for all postbaseline months (P < 0.001 for all tests performed).Conclusions: The relationship between CST and VALS in eyes with CRVO or HRVO after treatment with anti-vascular endothelial growth factor (VEGF) therapy is not simply linear. The usually modest correlations between OCT-measured CST and visual acuity belie strong left and right correlations present in 2-segment models. Post-treatment CST close to the estimated inflection points showed the best expected VALS. The SCORE2 participants with a post-treatment CST after treatment close to the estimated inflection points of 217 to 256 mm showed the best VALS. In patients treated with anti-VEGF for macular edema associated with CRVO or HRVO, a thinner retina is not always associated with better VALS. Financial Disclosure(s): Proprietary or commercial disclosure may be found in the Footnotes and Disclo-sures at the end of this article. Ophthalmology 2023;130:1066-1072 (c) 2023 by the American Academy of Ophthalmology
引用
收藏
页码:1066 / 1072
页数:7
相关论文
共 50 条
  • [31] Glaucoma and visual outcome in central retinal vein occlusion
    Moisseiev, J
    Desatnik, H
    Cohen, Y
    Lusky, A
    Melamed, S
    ACTA OPHTHALMOLOGICA SCANDINAVICA, 1996, 74 (04): : 368 - 371
  • [32] Baseline Characteristics and Response to Treatment of Participants With Hemiretinal Compared With Branch Retinal or Central Retinal Vein Occlusion in the Standard Care vs COrticosteroid for REtinal Vein Occlusion (SCORE) Study
    Scott, Ingrid U.
    VanVeldhuisen, Paul C.
    Oden, Neal L.
    Ip, Michael S.
    Domalpally, Amitha
    Doft, Bernard H.
    Elman, Michael J.
    Blodi, Barbara A.
    ARCHIVES OF OPHTHALMOLOGY, 2012, 130 (12) : 1517 - 1524
  • [33] Outcomes in patients with retinal vein occlusion with good baseline visual acuity
    Jessica C. Liu
    Thanvi Vatti
    Kanika Seth
    Carolina C. S. Valentim
    Aleksandra V. Rachitskaya
    Rishi P. Singh
    Eye, 2023, 37 : 3203 - 3208
  • [34] Outcomes in patients with retinal vein occlusion with good baseline visual acuity
    Liu, Jessica C. C.
    Vatti, Thanvi
    Seth, Kanika
    Valentim, Carolina C. S.
    Rachitskaya, Aleksandra V.
    Singh, Rishi P.
    EYE, 2023, 37 (15) : 3203 - 3208
  • [35] Effects of intravitreal bevacizumab on reduced visual acuity and macular thickness secondary to branch retinal vein occlusion
    Eltutar, Kadir
    Acar, Fahreddin
    Dincer, Nurhan
    Zirtiloglu, Sibel
    Unsal, Rkan
    CLINICAL OPHTHALMOLOGY, 2013, 7 : 1777 - 1780
  • [36] Intravitreal Ranibizumab Treatment for Macular Edema Associated with Central Retinal Vein Occlusion and Hemiretinal Vein Occlusion: Cases Reports
    Matias, Joao
    Matos, Rita
    OPHTHALMOLOGICA, 2014, 232 : 74 - 75
  • [37] Glaucoma as a prognostic factor of central retinal vein occlusion: visual and anatomical outcomes and occurrence of ischaemic central retinal vein occlusion
    Kim, You Na
    Shin, Joong Won
    Park, Yu Jeong
    Lee, Joo Yong
    Kim, June Gone
    Yoon, Young Hee
    Kim, Yoon Jeon
    ACTA OPHTHALMOLOGICA, 2021, 99 (04) : E523 - E530
  • [38] Retinal oximetry in central retinal vein occlusion
    Jeppesen, S. K.
    Bek, T.
    ACTA OPHTHALMOLOGICA, 2017, 95
  • [39] Relationship between retinal blood flow and cytokines in central retinal vein occlusion
    Hidetaka Noma
    Kanako Yasuda
    Tatsuya Mimura
    Akemi Ofusa
    Masahiko Shimura
    BMC Ophthalmology, 20
  • [40] Relationship between retinal blood flow and cytokines in central retinal vein occlusion
    Noma, Hidetaka
    Yasuda, Kanako
    Mimura, Tatsuya
    Ofusa, Akemi
    Shimura, Masahiko
    BMC OPHTHALMOLOGY, 2020, 20 (01)